Cash Flow Rossari Biotech Cash flow Statement
Figures in Cr
Consolidated Cash Flow Results
Mar'26
Mar'25
Mar'24
Mar'23
Mar'22
Mar'21
No of Months
12
12
12
12
12
12
Profit Before Tax
202.00
185.00
177.00
144.00
136.00
106.00
Adjustment
85.00
84.00
76.00
82.00
55.00
20.00
Changes In working Capital
-153.00
-72.00
-156.00
-27.00
-112.00
-48.00
Cash Flow after changes in Working Capital
133.00
196.00
97.00
199.00
79.00
79.00
Cash Flow from Operating Activities
65.00
137.00
43.00
151.00
29.00
47.00
Cash Flow from Investing Activities
-220.00
-183.00
-103.00
-180.00
-298.00
-37.00
Cash Flow from Financing Activities
186.00
64.00
16.00
60.00
291.00
-24.00
Net Cash Inflow / Outflow
31.00
19.00
-44.00
31.00
22.00
-14.00
Opening Cash & Cash Equivalents
44.00
25.00
69.00
37.00
15.00
29.00
Cash & Cash Equivalent on Amalgamation / Take over / Merger
0.00
0.00
0.00
0.00
0.00
0.00
Cash & Cash Equivalent of Subsidiaries under liquidations
0.00
0.00
0.00
0.00
0.00
0.00
Translation adjustment on reserves / op cash balances foreign subsidiaries
0.00
0.00
0.00
0.00
0.00
0.00
Effect of Foreign Exchange Fluctuations
0.00
0.00
0.00
0.00
0.00
0.00
Closing Cash & Cash Equivalent
75.00
44.00
25.00
69.00
37.00
15.00
Figures in INR Cr
Seasonal companies are compared with the same quarter last year
Seasonal companies are compared with the same quarter last year
Compare Cash Flow Results of Rossari Biotech
Figures in Cr
consolidated Cash Flow Results
Change(INR)
Change(%)
Profit Before Tax
202.52
248.59
-46.00
-18.53%
Adjustment
85.17
-30.71
115.00
377.34%
Changes In working Capital
-153.86
17.56
-170.00
-976.20%
Cash Flow after changes in Working Capital
133.83
235.44
-102.00
-43.16%
Cash Flow from Operating Activities
65.07
168.12
-103.00
-61.30%
Cash Flow from Investing Activities
-220.29
-29.92
-191.00
-636.26%
Cash Flow from Financing Activities
186.32
-99.54
285.00
287.18%
Net Cash Inflow / Outflow
31.11
38.66
-7.00
-19.53%
Opening Cash & Cash Equivalents
44.2
348.14
-304.00
-87.30%
Cash & Cash Equivalent on Amalgamation / Take over / Merger
0
0
0.00
0.00%
Cash & Cash Equivalent of Subsidiaries under liquidations
0
0
0.00
0.00%
Translation adjustment on reserves / op cash balances foreign subsidiaries
0
0
0.00
0.00%
Effect of Foreign Exchange Fluctuations
0
0
0.00
0.00%
Closing Cash & Cash Equivalent
75.31
386.8
-311.00
-80.53%
Cash Flow - Snapshot (Consolidated) - Mar'26
YoY Growth in year ended Mar 2026 is -52.66% vs 217.71% in Mar 2025
Mar'26
Mar'25
Change(%)
Cash Flow from Operating Activities
65.07
137.44
-52.66%
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
